Effect of a new calcium antagonist on hemodynamics at rest and exercise loading in patients with essential hypertension.
MPC-1304 ((+-)-methyl 2-oxopropyl 1,4-dihydro 2,6-dimethyl-4-(2-nitrophenyl)-3,5-pyridinedicarboxylate, CAS 86780-90-7), a new calcium antagonist, was orally administered to 10 outpatients with mild essential hypertension. It was observed that MPC-1304 inhibited elevations of blood pressure both at rest and under exercise loading without any adverse hemodynamic effects. The findings obtained indicated that MPC-1304 would be clinically useful in the treatment of hypertensive patients undergoing therapy while continuing normal everyday activities including physical exertion.
Suzuki
S
S
Nagasaki Prefectural Tarami Hospital, Japan.
Hashimoto
T
T
Kusano
S
S
Kapuku
K
K
Utsunomiya
T
T
Yano
K
K
D000368:Aged; D001794:Blood Pressure / Q000187:drug effects; D002121:Calcium Channel Blockers / Q000009:adverse effects / Q000494:pharmacology* / Q000627:therapeutic use; D004095:Dihydropyridines / Q000009:adverse effects / Q000494:pharmacology* / Q000627:therapeutic use; D015444:Exercise / Q000502:physiology*; D005260:Female; D006439:Hemodynamics / Q000187:drug effects*; D006801:Humans; D006973:Hypertension / Q000188:drug therapy / Q000503:physiopathology*; D008297:Male; D008875:Middle Aged; D009200:Myocardial Contraction / Q000187:drug effects; D011674:Pulse / Q000187:drug effects; D012146:Rest / Q000502:physiology*; D014655:Vascular Resistance / Q000187:drug effects
D002121:Calcium Channel Blockers; D004095:Dihydropyridines; C059427:aranidipine